Pharmaceuticals and Healthcare Reports Anti-Neutrophil Cytoplasmic Antibody-Associated Va

Anti-Neutrophil Cytoplasmic Antibody-
Associated Vasculitis (ANCA Vasculitis)
Market Pipeline Review Report 2016
“The report provides comprehensive information on
the therapeutics under development for Anti-
Neutrophil Cytoplasmic Antibody-Associated
Vasculitis (ANCA Vasculitis), complete with analysis
by stage of development, drug target, mechanism
of action (MoA), route of administration (RoA) and
molecule type.”
Summary
The Report provides an overview of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
(ANCA Vasculitis) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Anti-
Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in therapeutic development for Anti-Neutrophil
Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) and features dormant and
discontinued projects.
Complete Report Available @ http://www.radiantinsights.com/research/anti-neutrophil-
cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-pipeline-review-h2-2016
Radiant Insights's report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from
Follow Us: